Virtual Library

Start Your Search

Yu Teng

Author of

  • +

    EP1.01 - Advanced NSCLC (ID 150)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.01-27 - Preliminary Study on Immune Checkpoint and EMT Feature of CTCs in Advanced Non-Small Cell Lung Cancer Patients (ID 625)

      08:00 - 18:00  |  Author(s): Yu Teng

      • Abstract
      • Slides


      Non-small cell lung cancer (NSCLC) is the most common malignant tumor with high morbidity and mortality. Platinum-containing chemotherapy is the standard first-line chemotherapy regimen for patients with advanced NSCLC. However, 65-75% patients would progress after a few weeks of chemotherapy treatment. The programmed cell death 1 (PD-1)/PD-1 ligand 1(PD-L1) has become the rising star of cancer research only because their development of PD-1/PD-L1 inhibitors has bring cancer patient new hope and changed the landscape of NSCLC therapy. Nevertheless, the high degree of non-responders demonstrates that we are still far from completely understanding the events underlying tumor immune resistance. Circulating tumor cells (CTCs), as an accessible source of tumor for biologic characterization that can be serially obtained with minimally invasive procedure. Studies have shown that presence of PD-L1 on CTC might predict resistance to anti-PD-1 therapy, and PD-L1 positive CTCs usually present an elongated morphology, which was associated with epithelia-mesenchymal transition (EMT). Those research provided evidence that CTC might be a promising object to predict whether the patient could be benefit from the second-line checkpoint inhibitor treatment. In this prospective cohort study, we aimed to describe the molecular background of CTCs from patients with disease progress after first-line chemotherapy.


      We consecutive enroll patients who have been treated with platinum-containing chemotherapy in our hospital from May 2018 to the present, and have been assessed for disease progression (PD) by RECIST version 1.1. 6.5ml of peripheral blood was collected before further treatment. Then we enriched the CTCs and performed in situ co-detection of PD-L1 and EMT marker (Vimentin) using SE-iFISH technology.


      To date we have recruited 13 eligible patients. Detectable CTCs counts range from 1 to 22 in 6.5ml blood. Among them, 4 samples presented PD-L1 positive, 4 samples presented Vimentin positive. Only 1 sample has co-expression of PD-L1 and Vimentin.


      Above results proved that SE-iFISH method could be used for CTC enrichment and detection. Next step, we will wait for those patients’ checkpoint inhibitor treatment outcome, analysis the correlation between PD-L1 and Vimentin co-expression and patient response. At the same time, we will continue to include cases, collect CTC samples and evaluate the expression of PD-L1 and Vimentin on CTCs.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.